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Immune profiles and DNA methylation
alterations related with non‑muscle‑invasive
bladder cancer outcomes
Ji‑Qing Chen1, Lucas A. Salas1, John K. Wiencke2, Devin C. Koestler3, Annette M. Molinaro2,
Angeline S. Andrew4, John D. Seigne5, Margaret R. Karagas1, Karl T. Kelsey6 and Brock C. Christensen1,7,8*

Abstract
Background: Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent monitoring because ≥ 70% will
have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity making
bladder cancer the most expensive cancer to treat per capita. There is an urgent need to expand the understanding
of markers related to recurrence and survival outcomes of NMIBC.
Methods and results: We used the Illumina HumanMethylationEPIC array to measure peripheral blood DNA methyl‑
ation profiles of NMIBC patients (N = 603) enrolled in a population-based cohort study in New Hampshire and applied
cell type deconvolution to estimate immune cell-type proportions. Using Cox proportional hazard models, we identi‑
fied that increasing CD4T and CD8T cell proportions were associated with a statistically significant decreased hazard
of tumor recurrence or death (CD4T: HR = 0.98, 95% CI = 0.97–1.00; CD8T: HR = 0.97, 95% CI = 0.95–1.00), whereas
increasing monocyte proportion and methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) were associated
with the increased hazard of tumor recurrence or death (monocyte: HR = 1.04, 95% CI = 1.00–1.07; mdNLR: HR = 1.12,
95% CI = 1.04–1.20). Then, using an epigenome-wide association study (EWAS) approach adjusting for age, sex,
smoking status, BCG treatment status, and immune cell profiles, we identified 2528 CpGs associated with the hazard
of tumor recurrence or death (P < 0.005). Among these CpGs, the 1572 were associated with an increased hazard and
were significantly enriched in open sea regions; the 956 remaining CpGs were associated with a decreased hazard
and were significantly enriched in enhancer regions and DNase hypersensitive sites.
Conclusions: Our results expand on the knowledge of immune profiles and methylation alteration associated with
NMIBC outcomes and represent a first step toward the development of DNA methylation-based biomarkers of tumor
recurrence.
Keywords: DNA methylation, Non-muscle-invasive bladder cancer, Immune profile, Immunomethylomic,
Recurrence, Survival
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Background
In 2021, the estimated number of bladder cancer deaths
is projected to be 17,200, with an estimated number of
new cases of 83,730 in the USA. Bladder cancer is the
fourth most common cancer among men and twelfth
most common among women, which may in part be due
to smoking prevalence rates being higher in men than
women as cigarette smoking accounts for half of all cases
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(47%) in the USA. [1]. Seventy-five percent of bladder
cancers are diagnosed as low-grade non-muscle invasive
tumors, NMIBC [2]. Cystoscopy is used for diagnosis
(biopsy) with transurethral excision of localized tumors
as the primary treatment [3–5]. Although transurethral
excisions can successfully control the disease and mortality from bladder cancer among patients with localized
tumors is low, 45% of NMIBC cases have recurrences
within 12 months of surgery [6]. In addition, frequent
invasive follow-up via cystoscopy without prognostic
markers leads to significant patient morbidity and comes
with a considerable cost burden to the health care system, estimated at approximately $4 billion dollars annually in the USA [7]. To control the patient and healthcare
burdens associated with NMIBC, there is an imminent
need for biomarkers to identify those at the highest risk
of tumor recurrence.
Peripheral blood immune profiles have been associated
with different outcomes in bladder cancer patients and
may have clinical utility for NMIBC prognosis [8–13].
For instance, in NMIBC, patients with elevated neutrophil-to-lymphocyte ratio (NLR) had poorer cancerspecific survival than patients with lower NLR [9–11].
Thus, elevated NLR could be a potential predictor of
overall survival and cancer-specific survival for this disease. Other studies have indicated that bladder cancer
patients with increased lymphocyte-to-monocyte ratio
had poorer overall survival and cancer-specific survival
[12, 13]. In addition, Bacillus Calmette–Guérin (BCG), a
commonly used intravesical immunotherapy for NMIBC
administered post-surgery, has been reported to reduce
the proportion of natural killer T cells, memory CD4T,
CD8T, and regulatory T cells in the peripheral blood of
NMIBC patients [8]. Together, circulating immune profiles might be promising markers for reducing adverse
outcomes in NMIBC patients. Previous studies have
relied on complete blood count differential (CBC) tests
to determine immune profile variables [14, 15]. The CBC
test relies on fresh blood samples and is incapable of providing proportions of specific lymphocyte subtypes [16].
Our prior work has established methods to infer the
immune profiles in archival samples using immune celltype-specific DNA methylation [17, 18]. DNA methylation plays an essential role in gene regulation for cell
lineage specification [19, 20]. Differentially methylated regions (DMRs) have been used to distinguish cell
types, including leukocyte subtypes, and form the basis
of reference-based deconvolution methods for estimating specific immune cell-type proportions [18, 21,
22]. Compared with cytological methods for determining cell type abundances and proportions, such as flow
cytometry, DNA methylation-based cell-type deconvolution does not require a fresh substrate, intact cells, or
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batch-sensitive reagents, is reproducible and cost-effective relative to time-sensitive blood processing [23, 24].
With cell-type deconvolution approaches, it is possible to
identify immune cell-type profiles and test their relationship with cancer outcomes in archived samples [25]. This
study used the archival blood samples of NMIBC patients
to test the association between the immune profiles and
outcomes in bladder cancer patients.
In the present study, we sought to identify immune
profiles and epigenetic features associated with disease
recurrence in the hope that such information might help
improve the management of NMIBC. Here, we hypothesized that CpG-specific DNA methylation and DNA
methylation-derived immune cell profiles are associated
with recurrence-free survival in NMIBC patients. We
used archival blood samples from a population-based
case–control study to obtain genome-scale DNA methylation profiles. We then investigated the association
between the methylation-derived immune profiles and
outcomes in NMIBC patients. Preliminary work from
our group observed an association between methylationderived NLR (mdNLR) and survival in bladder cancer
patients using a smaller sample size (223 cases) and an
early genome-scale methylation array (HumanMethylation27K array) [26]. In this study, we increased the sample size (603 cases), used a new more comprehensive
array (HumanMethylationEPIC array) with 30 times as
many measured features, and a new cell type deconvolution library [18] to estimate immune cell-type proportions. An epigenome-wide association study (EWAS) and
enrichment analyses were used to determine possible
CpG sites and gene sets associated with recurrence-free
survival.

Results
Profiles of DNA methylation were obtained from 685
peripheral blood samples using the Human MethylationEPIC array. Eighty-two subjects were excluded due to
low-quality CpG value or bisulfite intensity (n = 11), or
without muscle-invasive status, histopathology re-review,
tumor grade, smoking status, and pack-years (n = 71)
(Fig. 1). The remaining subjects (N = 603) included in
the study group were 75.8% men (n = 457), 82.9% eversmokers (n = 500), and had a median age of 66 (Table 1).
We estimated the cell-type proportions for each patient
using methylation values by performing FlowSorted.
Blood.EPIC (see Additional file 7: Figure S1 for the distribution). Neutrophil-to-lymphocyte ratio (NLR) was then
calculated according to the ratio of neutrophil proportion
to lymphocyte proportion (B cell + CD4T cell + CD8T
cell + NK cell), and the median methylation-derived NLR
(mdNLR) was 1.97. Further details of study population
characteristics are described in Table 1.
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Fig. 1 Flow chart of study

To characterize 10-year recurrence-free survival (RFS),
we generated Kaplan–Meier curves for each covariate
and fit a Cox proportional hazard regression model for
univariate analyses and multivariable analyses, respectively. In the Kaplan–Meier analysis, the NMIBC patients
aged > 65 had a worse probability of RFS compared
with the NMIBC patients with age ≤ 65 (P = 0.0006).
Females had a greater probability of RFS compared with
males (P = 0.002), and the NMIBC patients with highgrade tumors (grade 3 + 4) had a lesser probability of
RFS than those with low-grade tumors (grade 1 + 2)
(P = 8.0 × 10−5). Ever-smokers had a worse probability
of RFS than the NMIBC patients who were never smokers (P = 3.0 × 10−4). NMIBC patients with low mdNLR
had a greater probability of RFS than the patients with
high mdNLR (P = 0.002) (Fig. 2). Consistent with the
Kaplan–Meier results, in a multivariable Cox model,
age > 65 (HR = 1.01, 95% CI = 1.00–1.03), high tumor
grade (HR = 1.48, 95% CI = 1.17–1.87), ever-smoking

(HR = 1.65, 95% CI = 1.22–2.25), and mdNLR (HR = 1.12,
95% CI = 1.04–1.20) were significantly associated with an
increased hazard of RFS (Table 2).
We next investigated the association between
immune cell-type proportions and RFS in multivariable models. CD4T (HR = 0.98, 95% CI = 0.97–1.00)
and CD8T cell proportion (HR = 0.97, 95% CI = 0.95–
1.00) were significantly associated with the decreased
hazard of RFS. Monocyte cell proportion (HR = 1.04,
95% CI = 1.00–1.07) was significantly associated with
the increased hazard of RFS. Both B cell and NK cell
proportion hazard estimates were < 1 but not statistically significant (Additional file 1). We also examined
the 10-year overall survival (OS) in univariate models and the multivariable models. Observed associations with RFS were consistent for OS for: age, male,
high tumor grade, ever-smoking, and mdNLR (Table 3
and Additional file 7: Figure S2). In addition, CD4T,
CD8T, B cell, and NK cell proportion were significantly
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Table 1 Characteristics of subjects after excluding subjects with
missing values
NMIBC (n = 603)
Age
Median (Q1, Q3)

66 (57,71)

Sex
Male

457 (75.8%)

Female

146 (24.2%)

Tumor grade
Grade 1

290 (48.1%)

Grade 2

162 (26.9%)

Grade 3

125 (20.7%)

Grade 4

26 (4.3%)

Smoking status
Never

103 (17.1%)

Ever

500 (82.9%)

BCG: immunotherapy
No

514 (85.2%)

Yes

89 (14.8%)

NLR
Median (Q1, Q3)

1.97 (1.40, 2.93)

10-year dead status
Alive

423 (70.1%)

Deceased

180 (29.9%)

10-year survival
Median (Q1, Q3)

120.0 (105, 120)

10-year recurrence status
No

193 (32.0%)

Yes

295 (48.9%)

Missing

115 (19.1%)

10-year recurrence
Median (Q1, Q3)

17.7 (6.9, 67.1)

Missing

115

Exclude subjects with missing values in muscle-invasive status, pathology
reviewing status, tumor grade, smoking status, or pack-years

associated with the decreased hazard of death; neutrophil cell proportion was significantly associated with
the increased hazard of death (Additional file 2).
Next, we assessed the relation of NMIBC patient
outcomes with DNA methylation. First, Cox proportional hazards models were fit for each CpG controlling for age, stratified sex, tumor grade, smoking
status, and stratified BCG receiving status. Without
adjustment for immune cell proportions, we identified 27,575 CpGs whose methylation was associated
with a significant (P < 0.005) difference in hazard of
RFS (Fig. 3A, Additional file 3). We then conducted
similar analyses controlling for age, sex, tumor grade,
smoking status, BCG status, and winsorized immune
cell proportions. As expected and demonstrating the

importance of adjusting for cell-type proportions, the
fully adjusted models were attenuated and identified
2528 CpGs whose methylation was associated with a
significant difference (P < 0.005) in the hazard of RFS.
The 10 CpGs most strongly (with smallest P-value)
associated with hazard of RFS corresponded to 10
genes: TMCO4 (cg04738197), LENG9 (cg12057190),
CDC42EP5
(cg12057190),
LNP1
(cg02540094),
TOMM70A (cg02540094), RUNX2 (cg08012149),
TBXAS1 (cg01584377), SSH1 (cg16237760), SFXN2
(cg08609163), and COG3 (cg06172950). 1572 CpGs
were associated with the increased hazard of RFS, and
956 CpGs were associated with the decreased hazard
of RFS (Fig. 3B). The complete list of RFS-associated
CpGs is provided in Additional files 4 and 5.
To gain a better understanding of the regions where
the hazard-associated CpGs were located, we tested for
enrichment of CpG island region context among CpG
loci associated with a significant change in the hazard
of RFS. We found that 1572 CpGs associated with the
increased hazard of RFS were significantly enriched in
the open sea (OR = 1.14, 95% CI = 1.03–1.27) and were
significantly depleted in CpG island S Shore regions
(OR = 0.82, 95% CI = 0.67–0.99). The 956 CpGs associated with a decreased hazard of RFS were significantly
enriched in CpG island N Shore regions (OR = 1.30,
95% CI = 1.06–1.57) and were significantly depleted in
CpG island (OR = 0.60, 95% CI = 0.46–0.78) (Fig. 4A).
We also tested for enrichment of other gene regulatory
regions among CpG loci associated with a significant
change in the hazard of RFS.
Location of CpGs in regulatory regions also was
investigated and the CpGs associated with the
increased hazard of RFS were significantly enriched
in enhancer regions (OR = 1.78, 95% CI = 1.43–2.18),
DNase hypersensitive sites (DHS) (OR = 1.25, 95%
CI = 1.13–1.40), 5’UTR regions (OR = 1.37, 95%
CI = 1.17–1.60) and gene body (OR = 1.15, 95%
CI = 1.04–1.27); however, these CpGs were significantly depleted in regions 200–1500 bps upstream of
the transcription start site (TSS1500) (OR = 0.85, 95%
CI = 0.73–0.99). In addition, while the CpGs associated with a decreased hazard were strongly enriched
in enhancer regions (OR = 4.18, 95% CI = 3.44–5.05)
and DHS (OR = 2.46, 95% CI = 2.13–2.86), they were
depleted for TSS200 (OR = 0.70, 95% CI = 0.48–0.99),
gene body (OR = 0.85, 95% CI = 0.74–0.97) and transcription factor binding sites (TFBS) (OR = 0.68, 95%
CI = 0.55–0.83) (Fig. 4B). Using the CpGs associated
with hazard of RFS from cell-type unadjusted models
in tests for enrichment gave results that were largely
consistent with those above based on CpGs from fully
adjusted models (Additional file 7: Figure S3).
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Fig. 2 Kaplan–Meier analysis of 10-year recurrence-free survival (RFS). 10-year RFS curves stratified by A age, B sex, C tumor grade, D smoking
status, E BCG treatment status or F mdNLR level. P-values for log-rank tests are shown

To further understand the biological function of the
hazard-associated CpGs, Gene Set Enrichment Analysis (GSEA) Molecular Signature Database (MSigDB)
was used to explore the potential gene sets which might
associate with the tumor recurrence or death of NMIBC
patients. The input was 2528 RFS associated CpGs
from the Cox model EWAS adjusting for immune cell

composition. In the top 10 hazard-associated gene sets in
gene ontology (GO) terms, some gene sets were related
to neurological system processing (Additional file 7: Figure S4A), and most related genes were associated with
the increased hazard of RFS in NMIBC (Additional file 7:
Figure S4B). Since mdNLR was associated with the hazard of recurrence or death of NMIBC, we were interested
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Table 2 Cox proportional hazards 10-year recurrence-free survival models
n (%) e
 vent#

Age

373 (61.9)

n (%) no-events#

230 (38.1)

Event occurrence months

Multivariable$ model

Mean

HR (95% CI)

P value

1.01 (1.00–1.03)

0.024

Median

65.6

62.0

Tumor grade
1+2

3+4

263 (58.2)

189 (41.8)

69.9

79.0

Referent group

110 (72.8)

41 (27.2)

52.8

26.7

1.48 (1.17–1.87)

1.0E−3

Smoking status
Non-smoker

47 (45.6)

56 (54.4)

82.3

120.0

Referent group

Ever-smoker

326 (65.2)

174 (34.8)

62.2

51.9

1.65 (1.22–2.25)

1.0E−3

mdNLR*

373 (61.9)

230 (38.1)

65.6

62.0

1.12 (1.04–1.20)

3.0E−3

HR: hazard ratio, CI: confidence interval, mdNLR: methylation-derived neutrophil to lymphocyte ratio
Stratification was used on sex and BCG treatment status for proportional assumption
$

The model controlling for age, sex, tumor grade, smoking status, BCG treatment status, and mdNLR

*

Winsorization was used on the top 2% values for fitting linearity assumption

#

Initial recurrence or the death whose cause was unknown

Table 3 Cox proportional hazards 10-year overall survival models
n (%) deceased

n (%) alive

Survival months
#

Age

180 (29.9)

423 (70.1)

Multivariable model

Mean

HR (95% CI)

P value

104.3

1.07 (1.04–1.08)

8.7E−9

Sex
Male

156 (34.1)

301 (65.9)

102.2

Referent group

Female

24 (16.4)

122 (83.6)

111.1

0.62 (0.40–0.96)

118 (26.1)

334 (73.9)

106.6

Referent group

62 (41.1)

89 (58.9)

97.7

1.54 (1.12–2.12)

0.032

Tumor grade
1+2

3+4

8.0E−3

Smoking status
Non-smoker

19 (18.4)

84 (81.6)

110.8

Referent group

Ever-smoker

161 (32.2)

339 (67.8)

103.0

1.66 (1.03–2.67)

0.039

BCG treatment
No

152 (29.6)

362 (70.4)

104.8

Referent group

Yes

28 (31.5)

61 (68.5)

101.9

1.04 (0.68–1.60)

0.842

mdNLR*

180 (29.9)

423 (70.1)

104.3

1.46 (1.32–1.60)

6.0E−15

HR: hazard ratio, CI: confidence interval, mdNLR: methylation-derived neutrophil to lymphocyte ratio
*

Winsorization was used on the top 2% values for fitting linearity assumption

All covariates modeled met proportionality assumptions #: the median survival month for each variable is 120

in immune-related gene sets. We checked the immunologic signature gene set, and the top 10 gene sets and their
genes were related to immune cell regulation. However,
only one gene set (BCELL VS MDC UP: up-regulated
genes in B cells compared with myeloid dendritic cells
after vaccination for influenza) consisting of 41 genes was
significantly associated with RFS (FDR < 0.05) (Additional
file 7: Figure S4C-D). Results from GO term analyses
using 27,575 CpGs from the cell-type unadjusted models
identified 5 pathways related to immunologic regulation
among the top 10 pathways. Further, in the immunologic

signature gene set specifically, we observed the top 10
pathways were associated with monocytes and lymphocytes (Additional file 7: Figure S5).
Locus overlap analysis (LOLA) was used to test the
enrichment of CpGs in genomic regions. As our analysis was conducted on blood samples, results focus on the
genomic regions within hematopoietic stem cells. When
controlling for immune cell profiles, the 2528 CpGs associated with the hazard of RFS in NMIBC patients were
most significantly enriched in Histone H3 acetylated at
lysine 9 and 14 (H3K9K14ac) (Q-value = 1.9 × 10−20)
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Fig. 3 Volcano plots of recurrence-free survival (RFS) associated CpGs from the epigenome-wide association study (EWAS) analyses. The Cox
multivariable model that was fitted in EWAS was shown in each plot. CpGs are colored in red (A) 12,105 CpGs were associated with the increased
hazard of NMIBC 10-year RFS, and 15,470 CpGs were associated with the decreased hazard of NMIBC 10-year RFS. (B) 1572 CpGs were associated
with the increased hazard of NMIBC 10-year RFS, and 956 CpGs were associated with the decreased hazard of NMIBC 10-year RFS

(Additional file 7: Figure S6A). LOLA results for the
27,575 CpGs associated with the hazard of RFS from cell
type unadjusted models were most significantly enriched
in cistrome of the promyelocytic leukemia protein (PML)
(Q-value < 0.05) (Additional file 7: Figure S6B).
We also ran a differentially methylated regions analysis
using DMRcate. In this study, we found 11 CpGs in a specific genome region overlapping with the gene BLCAP.
NMIBC patients without tumor recurrence or death
within 10 years had a higher mean of methylation levels for this region compared with NMIBC patients with

tumor recurrence or death within 10 years, and one CpG
in this region was significant (FDR = 2.63 × 10−14) (Additional files 6, 7: Figure S7).

Discussion
In this study, we tested whether immune profiles and
epigenetic features are associated with NMIBC recurrence. Although previous work observed the association
between NLR and overall survival in NMIBC patients, it
was in a smaller study sample and used DNA methylation
data from a dated (second generation) array platform
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Fig. 4 Genomic context enrichment analysis of CpG sites whose methylation state is significantly associated with recurrence-free survival.
Enrichment analysis of (A) relation to CpG island and (B) genomic context of NMIBC recurrence-free survival associated CpGs. The 2528 CpGs from
EWAS (P < 0.005) were tested for enrichment versus all modeled CpGs. The bar represents the 95% confidence interval. Mantel–Haenszel was used
to test RFS-associated CpGs enrichment of CpG island-related gnome context. An odds ratio larger than 1 means enrichment, and an odds ratio
smaller than 1 indicates depletion

with ~ 27,000 CpGs. In this study, our sample size was
nearly three times larger and DNA methylation data
was collected using the current genome-scale platform
(fourth generation), measuring ~ 860,000 CpGs for which
an optimized cell-type deconvolution library exists to
determine highly accurate immune cell-type proportions.

We extended tests of association with the patient outcomes beyond the methylation-derived neutrophil-tolymphocyte ratio (mdNLR) to include leukocyte-specific
cell-type proportions. Our findings suggest that elevated
mdNLR increased the hazard of RFS in NMIBC patients.
These findings are consistent with previous studies
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demonstrating that NLR was significantly higher in highrisk NMIBC patients [27], and increased NLR was positively associated with poor prognosis [28, 29]. While past
studies have shown a significant association between
NLR and outcomes in NMIBC patients using the conventional method of CBC tests [30–32], this study uses NLR
derived from blood methylation profiles. Compared with
flow cytometry, estimation using the differentially methylated regions (DMR) library has several advantages: it
does not require long sample processing time, large volume of blood, or intact cells as DNA and 5-methylcytosine are both stable [33]. The advantage of our approach
is the ability to use archived samples that many investigators may already have. Moreover, utilizing blood samples
to monitor patient outcomes is less invasive compared
with a cystoscopy, the routine screening method. For
NMIBC patients with a high risk of tumor recurrence,
BCG is the standard intravesical immunotherapy to
induce immune system eliminating bladder cancer cells
that might be left after surgery [8, 34, 35], and therefore,
blood immune profile is a potential prognostic factor.
Immune profiling with DNA methylation data is a promising avenue for assessing NMIBC prognosis.
As NLR is composed of lymphocyte and neutrophil
proportions, we also considered the association between
each methylation-derived immune cell type proportion
and patient outcomes. Interestingly, increased CD4T and
CD8T cell proportions were associated with decreased
NMIBC recurrence-free survival and overall survival.
Prior work has shown that NMIBC patients with a high
CD4T cell count in BCG pretreatment microenvironment have a significantly prolonged recurrence-free survival compared to patients with a low CD4T cell count
[35]. In addition to the immune cell types explored in this
study, other cell types have been shown to affect NMIBC
development, such as GATA3 + T cells, regulatory T
cells, and tumor-associated macrophages [35]. Other
work showed an increased C
 D8+ILT2+ T cell proportion
was associated with a significantly increased hazard of
NMIBC recurrence [36]. Further, peripheral neutrophil
x platelet/lymphocyte was inversely correlated with highrisk NMIBC recurrence-free survival [37]. These results
demonstrate the potential of immune cell profiles in evaluating the prognosis of NMIBC patients, and future work
mapping DNA methylation profiles of additional immune
cell types and states could add detail to investigations of
immune profiles and bladder cancer outcomes. In addition, peripheral immune cell distribution is affected by
potentially residual confounding factors such as, infection [38], inflammation [39], lifestyles, treatments [40,
41], obesity [42], chronic alcohol consumption [43], and
type 2 diabetes [44]. Since our study includes hundreds
of subjects and has a decade or more of follow-up time,
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in the future, we will re-explore the effect of these residual confounding factors on the association of circulating
immune cell distribution and NMIBC outcomes. In the
future, we will perform higher resolution methylation cell
mixture deconvolution to resolve additional immune cell
types and employ blood count on prospectively collected
samples. Together, these data will allow us to understand
if specific subsets of neutrophils or lymphocytes contribute to high NLR in patients with poor outcomes.
Bacillus Calmette–Guérin (BCG) is the most commonly used immunotherapy for high-risk NMIBC.
After transurethral resection of bladder tumors, NMIBC
patients may receive BCG intravesical therapy to induce
an immune response in the bladder to attack cancer
cells. Previous studies have shown that tumor immune
environments may interact with BCG and interfere with
the efficacy of this therapy. For instance, IL-12 secreted
by BCG-induced monocytes was increased in NMIBC
patients without tumor recurrence, a phenomenon that
may involve the innate immune memory of circulating
monocytes [45]. Nevertheless, patients receiving BCG
in our study did not have peripheral immune cell profiles that differed from patients who were BCG naïve, and
BCG was not significantly associated with NMIBC outcomes. As the number of patients with BCG treatment
was relatively low (N = 89; 14.8%) and limited power to
observe possible therapy induced changes in peripheral
immune profiles, future work is needed to address the
potential associations of BCG with peripheral immune
profiles and patient outcomes. Most BCG-treated
patients were already high-risk. In addition, blood samples were collected only after surgery or initial BCG
treatment. To assess the changes in immune profiles over
time, having multiple blood draws is necessary for future
work.
This EWAS identified several CpGs associated with
NMIBC recurrence-free survival when controlling for
stratified sex, age, tumor grade, smoking status, stratified
BCG receiving status, and immune cell profiles. With a
P-value < 0.005, 2528 CpGs were found to be associated
with the hazard of RFS.
Among the top CpGs whose methylation was associated with NMIBC recurrence or death in the fully
adjusted models, some genes have been previously associated with bladder cancer. Slingshot homolog-1 (SSH1)
had a positive association with tumor grade, tumor invasion, and tumor recurrence of bladder cancer patients
[46]. Runt-related transcription factor 2 (RUNX2) is
a key factor of osteoblast differentiation and has been
reported to be associated with epithelial-mesenchymal
transition in bladder tumors. Furthermore, RUNX2 could
predict early recurrence in bladder cancer patients with
high accuracy [47, 48]. Similar to past studies, SSH1 and
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RUNX2 were associated with the increased risk of tumor
recurrence in our study. In addition, NMIBC patients
with tumor recurrence within ten years had significantly
higher methylation levels in the gene body of these two
genes compared with patients without tumor recurrence.
When not adjusting for immune cell profiles, 27,575
CpGs were associated with the decreased hazard of RFS.
The top 10 CpGs with the most significant P-value corresponded to 6 genes: BCL11A (cg24361098), TMCO4
(cg04738197),
MICALCL
(cg01518090),
GRAP2
(cg21012238), TRAM2 (cg15085626), and KIRREL
(cg10570484). While these genes have not been reported
to be associated with bladder cancer outcomes, they have
been reported to be involved in mechanisms promoting
cancer development in tumors [49–52] or blood [53, 54].
Although we measured blood methylation in this study,
we plan to measure tumor methylation and will explore
the association of CpGs in these genes with NMIBC outcomes. What was more interesting is that the model, with
or without controlling for immune cell profiles, led to
different results. While immune cell profiles are usually
not adjusted in the Cox model, we controlled for immune
cell profiles since the immune system plays a key role in
tumor development. This study presents a new perspective to demonstrate the difference between models with
or without adjusting for immune profiles, indicating
the need for further investigation on the involvement of
immune profiles in outcome analyses.
Through DMR analysis, we found NMIBC patients
with tumor recurrence or death within 10 years had a
lower methylation level in the BLCAP region compared
with patients without tumor recurrence or death. The
bladder cancer-associated protein (BLCAP) gene encodes
a protein that stimulates apoptosis. It has been reported
that loss of protein expression is associated with bladder
tumor progression, and the application of staining patterns for this protein could be a potential biomarker in
bladder cancer [55]. In functional analysis, strong nuclear
expression of BLCAP was associated with expression of
p-STAT3 and overall poor disease outcome. Additionally,
BLCAP was discovered to interact with STAT3 physically
and may involve the STAT3-mediated progression of precancerous lesions to invasive bladder tumors [56]. These
results were consistent with our finding that NMIBC
patients with poor outcomes had lower methylation levels in the BLCAP region. Since the model we used for
DMRs analysis was adjusted for immune cell profiles, we
are curious whether immune cells may play roles in the
interaction between BLCAP and STAT3 and will investigate this in the future. The CpG site with significantly
lower methylation (cg10642330) is located in the 5’ UTR
of BLCAP and the gene body of NNAT. The methylation
beta value of this CpG site in NNAT had been reported
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significantly higher in prostate cancer tissue relative to
adjacent normal tissues [57]. Though no CpG site in the
BLCAP region was significantly associated with the hazard of tumor recurrence or death in the adjusted EWAS,
five BLCAP CpGs (cg26083330, cg23757721, cg13790727,
cg03061677, and cg04489586) were associated in the
model not controlling for immune cell proportions (not
including the DMR analysis site cg10642330). In the
future, we will investigate the relation of BLCAP tumor
methylation with survival outcomes.
Our results reveal several features of peripheral blood
immune profiles that are associated with outcomes in
NMIBC patients. We showed that higher CD4 or CD8
proportions were associated with decreased hazard of
recurrence or death and further established that high
NLR is associated with an increased hazard of RFS. The
EWAS portion of our study also points to epigenetic
reprogramming within the immune compartment being
involved in tumor recurrence of NMIBC patients. Future
study in a prospective setting will assess the clinical utility of incorporating methylation in predicting hazard of
recurrence and shaping recommendations for disease
surveillance. In addition to immune cells, future work
examining cell-type proportions in tumor microenvironments of NMIBC patients is needed to understand
the relationship between peripheral immune profiles
with tumor-infiltrating immune profiles and patient outcomes. This work contributes to our understanding of
associations of methylation-derived immune profiles and
NMIBC patient outcomes and could further contribute
to developments in epigenetic biomarkers of cancer.

Conclusions
Here we demonstrate the associations of non-muscleinvasive bladder cancer outcomes with immune profiles.
In addition, we identify preliminary evidence of discrete
and regional CpG methylation associations with bladder
cancer outcomes. The findings could contribute to developing epigenetic biomarkers for recurrence-free survival
in non-muscle-invasive bladder cancer.
Methods
Study subjects and samples

The subjects and data used in this study are described
in more detail in prior publications [58–60]. Briefly,
subjects were recruited from all three phases of a New
Hampshire population-based bladder cancer case–control study [61]. The first wave of this study (phase 1) collected blood samples from 331 individuals diagnosed
with incident bladder cancer between July 1994 and
June 1998. The second study wave (phase 2) collected
blood samples from 243 individuals diagnosed between
July 1998 and December 2001. Finally, the third study
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wave (phase 3) obtained blood samples from 194 individuals recruited and diagnosed between July 2002 and
December 2004. All the subjects were identified using the
New Hampshire State Cancer Registry, hospital pathology departments, and hospital cancer registries, and all
blood samples were collected after the time of diagnosis
(time range: 20–1790 days). Among patients, 40 patients
received BCG treatment in phase 1, 29 patients received
BCG in phase 2, and 19 patients received BCG in phase
3. All patients with BCG treatment had blood drawn after
receiving BCG (time range: 7–1542 days). An outline of
data filtering and inclusion/exclusion criteria applied to
these data are shown in Fig. 1. Briefly, subjects without
muscle-invasive status, histopathology re-review, tumor
grade, smoking status, or pack-years were removed from
the study. Subjects that withstood the aforementioned
exclusion criteria were retained and used in downstream
statistical analyses.
DNA extraction, quantification, and bisulfite modification

Each blood sample was maintained at 4C and frozen
within 24 h of blood draw. A hundred μl buffy coat was
used to extract DNA. The QIAMP DNA blood & Tissue
kit was used to extract DNA from blood samples according to the manufacturer’s protocol. Extracted DNA was
quantified by using the Qubit 3.0 Fluorometer. After
bisulfite modification, an established 5 mC microarray
protocol optimized for Illumina methylation arrays was
used to determine the genome-wide 5mC profile. DNA
samples were subjected to bisulfite conversion (according to the manufacturer’s protocol of the Zymo EZ DNA
methylation Kit) with an input of 750 ng per sample and
whole-genome amplified prior to array hybridization.
Recovered substrate ssDNA were submitted for DNA
methylation array processing.
DNA methylation data

Bisulfite-modified DNA samples were measured for
their DNA methylation status using the MethylationEPIC array, which interrogates > 860,000 CpG sites. Probe
intensity data (iDAT files) from the EPIC methylation
array were processed for quality control via the R package minfi [62] and ENmix [63] in R version 3.6. After
quality control, 11 samples with low-quality CpG values
or bisulfite intensity (threshold: 7000) were excluded
from the study. The data were then normalized and
conducted background correction through preprocessNoob procedure from minfi. The ComBat [64] was used
to adjust for potential batch effect. Probes with a detection P > 1.0 × 10−6 in more than 10% of the samples were
excluded (32,414). Also, 98,826 probes, which are crossreactive, SNP-associated, and non-CpG (CpH) methylation [65], as well as 17,120 probes on sex chromosomes,
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were excluded. In total, 726,856 probes were used in
downstream statistical analyses in downstream statistical
analyses. IlluminaHumanMethylationEPICanno.ilm10b4.
hg19 [66] was used to annotate CpG sites. Relation to
CpG island was defined by the “Relation_to_Island” as
in the Illumina annotation used in the genomic context
analysis. ‘5’UTR,’ ‘Exon,’ ‘Gene Body,’ and ‘3’UTR’ contexts were defined by having ‘5UTR,’ ‘ExonBnd,’ ‘Body’
and ‘3UTR’ in UCSC_RefGene_Group. ‘Enhancer’ context
was defined by having a record in the Phantom5_Enhancers. ‘DHS’ context was defined by finding a record in the
DNase_Hypersensitivity_NAME. ‘TFBS’ context was
defined by having a record in the TFBS_NAME.
Statistical analysis

The estimation of cell-type proportions was processed
through the estimateCellCounts2 from the FlowSorted.
Blood.EPIC package in Bioconductor (version 3.9; [18]).
Methylation-derived neutrophil-to-lymphocyte ratio
(mdNLR) was calculated by performing cell-mixture
deconvolution to estimate the proportion of leukocyte
subtypes and the ratio of neutrophil proportion to lymphocyte proportion was then computed. Individual leukocyte cell-type proportions and mdNLR were included
in outcome analyses as continuous variables for Cox
proportional hazard regression. In addition, mdNLR
was dichotomized based on the median mdNLR for the
Kaplan–Meier method.
Ten-year overall survival was defined as the time interval from the date of initial diagnosis to death within
10 years (all deaths were related with bladder cancer).
Subjects who were alive or lost to follow-up were censored at the last follow-up. Ten-year recurrence-free
survival was defined as the time interval from the date
of initial diagnosis to the first tumor recurrence or death
(all causes), whichever occurred first within 10 years.
Patients alive and free of the disease or lost to followup were censored at the last follow-up. For both overall
and recurrence-free survival, patient survival times over
10 years were truncated at 10 years, and patients were
censored if the first tumor recurrence or death occurred
after 10 years. The median survival times for the two survival outcomes were estimated using the Kaplan–Meier
method. In multivariable analyses, Cox proportional hazard regression models were used to examine the association of each variable on bladder cancer outcomes and
were fit via coxph in the survival R package. The proportional hazards assumption was tested by using cox.zph
from the survival R package. The cox.zph function tests
the proportionality of all the predictors in Cox models by
creating interactions with time. As sex and BCG treatment status violated the proportional hazards assumption, stratification on both variables was included. The
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linearity assumption was examined via ggcoxfunctional
from the R survminer package, and methylation-derived
immune cell profiles were found to violate the linearity
assumption. Hence, winsorization was used on methylation-derived immune cell profiles. The winsorization cutpoint of each immune cell profile is shown in Additional
file 7: Figure S1. A P-value of < 0.05 was the significance
threshold on multivariable analysis. Cox model results
were presented using the stargazer R package.

with tumor recurrence within ten years or not” in
our designed model. In addition, the designed model
was adjusted for sex, age, tumor grade, smoking status, BCG receiving status, and immune cell profiles.
We relaxed the threshold for DMRs analysis using an
FDR-corrected P-value of < 0.1. Then, the visualizeGene
from the sesame package [70] was used for observing
the methylation levels of CpGs in regions identified by
DMRcate.

Epigenome‑wide association study (EWAS), enrichment
analysis, and differentially methylated regions (DMRs)
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Complete blood count differential; DMRs: Differentially methylated regions;
RFS: Recurrence-free survival; OS: Overall survival; HR: Hazard ratio; OR: Odds
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set enrichment analysis; MSigDB: Molecular signature database.

An epigenome-wide association study (EWAS) was performed using ewaff R package (https://github.com/peris
hky/ewaff ) to investigate the association of CpG-specific
DNA methylation and bladder cancer recurrence. We fit
Cox proportional hazards models independently to each
CpG, controlling for age, sex, tumor grade, smoking status, Bacillus Calmette–Guérin (BCG) receiving status,
and immune cell profiles. Since all P-values adjusted for
false discovery rate from EWAS results are higher than
0.05, we relaxed the threshold for genomic context and
enrichment analyses using a P-value of < 0.005.
For CpG sites associated (P < 0.005) with bladder tumor
recurrence, we examined whether those CpGs were
enriched in CpG island-related genomic context or regulatory regions via using Mantel–Haenszel tests, adjusted
for Illumina probe type to eliminate the difference in
distributions on genomic context. CpG island-related
genomic context includes open sea, north shelves, north
shores, islands, south shores, and south shelves. Regulatory regions include enhancers, DNase hypersensitivity sites, 5’UTR, TSS1500, TSS200, 1st Exon, Exon, gene
body, 3’UTR, and transcription factor binding sites. Next,
the Locus Overlap analysis (LOLA) R package in Bioconductor (version 1.20.0; [67]) was used to investigate
enrichment of genomic regions limited to tissue equal to
“hematopoietic stem cell.” Finally, gometh and gsameth
from the missMethyl package in Bioconductor (version
1.6.2; [68]) were used to test the enrichment of gene sets
for Gene Ontology (GO) terms and the C7: immunologic
signature gene set in the Gene Set Enrichment Analysis
(GSEA) Molecular Signature Database (MSigDB) cnetplot from the enrichplot package in Bioconductor (version 1.10.1; https://yulab-smu.top/biomedical-knowl
edge-mining-book/) was used to plot gene-concept network plots.
Differentially methylated regions were identified
and extracted through the dmrcate and extractRanges
from the DMRcate R package [69]. The inputs were
logit-transform of beta values (M-values). The phenotype of interest for comparison was “NMIBC patients
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